Journal Article > ResearchFull Text
AIDS. 23 October 2013; Volume 27 (Issue 16); DOI:10.1097/01.aids.0000432456.14099.c7
Laureillard D, Marcy O, Madec Y, Chea S, Chan S, et al.
AIDS. 23 October 2013; Volume 27 (Issue 16); DOI:10.1097/01.aids.0000432456.14099.c7
To analyze cases of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) in the CAMbodian Early versus Late Introduction of Antiretrovirals (CAMELIA) randomized trial designed to compare early (2 weeks) versus late (8 weeks) antiretroviral therapy (ART) initiation after tuberculosis treatment onset in Cambodia (NCT00226434).
Journal Article > ResearchFull Text
N Engl J Med. 20 October 2011; Volume 365 (Issue 16); DOI:10.1056/NEJMoa1013911
Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, et al.
N Engl J Med. 20 October 2011; Volume 365 (Issue 16); DOI:10.1056/NEJMoa1013911
Tuberculosis remains an important cause of death among patients infected with the human immunodeficiency virus (HIV). Robust data are lacking with regard to the timing for the initiation of antiretroviral therapy (ART) in relation to the start of antituberculosis therapy.
Journal Article > ResearchFull Text
Clin Infect Dis. 1 August 2014; Volume 59 (Issue 3); DOI:10.1093/cid/ciu283
Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C, et al.
Clin Infect Dis. 1 August 2014; Volume 59 (Issue 3); DOI:10.1093/cid/ciu283
Shortening the interval between antituberculosis treatment onset and initiation of antiretroviral therapy (ART) reduces mortality in severely immunocompromised human immunodeficiency virus (HIV)-infected patients with tuberculosis. A better understanding of causes and determinants of death may lead to new strategies to further enhance survival.
Journal Article > ResearchFull Text
Trop Med Int Health. 1 February 2007; Volume 12 (Issue 2); DOI:10.1111/j.1365-3156.2006.01786.x
Janssens B, Van Herp M, Goubert L, Chan S, Uong S, et al.
Trop Med Int Health. 1 February 2007; Volume 12 (Issue 2); DOI:10.1111/j.1365-3156.2006.01786.x
OBJECTIVES: To compare the efficacy and tolerability of dihydroartemisinin-piperaquine (DHA-PQP) with that of a 3-day regimen of mefloquine and artesunate (MAS3) for the treatment of uncomplicated falciparum malaria in Cambodia. METHOD: Randomized open-label non-inferiority study over 64 days. RESULTS: Four hundred and sixty-four patients were included in the study. The polymerase chain reaction genotyping-adjusted cure rates on day 63 were 97.5% (95% confidence interval, CI, 93.8-99.3) for DHA-PQP and 97.5% (95% CI, 93.8-99.3) for MAS3, P = 1. There were no serious adverse events, but significantly more episodes of vomiting (P = 0.03), dizziness (P = 0.002), palpitations (P = 0.04), and sleep disorders (P = 0.03) reported in the MAS3 treatment group, consistent with the side-effect profile of mefloquine. CONCLUSIONS: DHA-PQP was as efficacious as MAS3, but much better tolerated, making it more appropriate for use in a routine programme setting. This highly efficacious, safe and more affordable fixed-dose combination could become the treatment of choice for Plasmodium falciparum malaria in Cambodia.